Volume 26, Issue 3 (5-2019)                   RJMS 2019, 26(3): 13-23 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Orangi E, Motovali-Bashi M, Tabatabaeian M. Evaluating the clinical importance of long-non coding RNA MALAT1 expression in breast cancer. RJMS 2019; 26 (3) :13-23
URL: http://rjms.iums.ac.ir/article-1-5551-en.html
Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran , mbashi@sci.ui.ac.ir
Abstract:   (3457 Views)
Background: Breast cancer is one of the major causes of illness and mortality among women. Long non-coding RNAs (LncRNAs) have important role in tumor development and progression. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a lncRNA that deregulates in several cancers, however, its value in the diagnosis of breast cancer is unclear. This study was conducted to investigate the MALAT1 expression levels in breast tumor tissue, its association with tumor clinical featuresand its diagnostic value as a biomarker in breast cancer.
Methods: In this study, the expression level of MALAT1 was measured in 31 breast tumor tissues and 31 adjacent normal tissues by real-time polymerase chain reaction. The MALAT1 expression alteration between the tumor and normal tissues and its association with clinical characteristics were analyzed with t-test and one-way ANOVA, respectively. The MALAT1 role as a biomarker was investigated by ROC curve.
Results: MALAT1 expression level in tumor tissues to adjacent normal tissues showed a significant decrement of 2.87 times (fold change= 0.348, p<0.001). Also, there was a positive and significant correlation between MALAT1 expression and patient's age and tumor invasive features (p <0.05). The ROC curve results showed that the area under the curve was significant and equal to 0.773. The sensitivity and specificity of MALAT1 as biomarker were 71.43 and 91.67, respectively.
Conclusion: The results of this study showed that the MALAT1 has a significant reduction in breast cancer and can act as a biomarker in diagnosing patients from healthy individuals.
 
Full-Text [PDF 1551 kb]   (1408 Downloads)    
Type of Study: Research | Subject: Genetic

References
2. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin; 2018.68(1):7-30.
3. 2. Sørensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, et al. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat; 2013.142(3):529-36.
4. 3. Enayatrad M, Amoori N, Salehiniya H. Epidemiology and trends in breast cancer mortality in Iran. Iran J Public Health; 2015.44(3):430.
5. 4. Asadpour A. Isfahan: First degree of cancer in Iran. Jame Jam; 2006.1942:15.
6. 5. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S. SEER cancer statistics review, 1975-2011. Bethesda (MD): National Cancer Institute; 2014. Basedon November 2013 SEER data submission, posted to the SEER web site. 2013.
7. 6. Zhang Y, Zhang K, Luo Z, Liu L, Wu L, Liu J. Circulating long non‐coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis ofbreast cancer. Thoracic Cancer; 2016.7(6):627-32.
8. 7. Cerk S, Schwarzenbacher D, Adiprasito JB, Stotz M, Hutterer GC, Gerger A, et al. Current status of long non-coding RNAs in human breast cancer. Int J Mol Sci; 2016.17(9):1485.
9. 8. Mallory AC, Shkumatava A. LncRNAs in vertebrates: advances and challenges. Biochimie; 2015.117:3-14.
10. 9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell; 2004.116(2):281-97.
11. 10. Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers; 2016.2016.
12. 11. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol;
13. 2011.21(6):354-61.
14. 12. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nature Rev Genet; 2009.10(3):155.
15. 13. Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and its role in cancer metastasis. Oncol Res Featur Preclin Clin Cancer Ther; 2016.23(5):205-17.
16. 14. Bayoumi AS, Sayed A, Broskova Z, Teoh J-P, Wilson J, Su H, et al. Crosstalk between long noncoding RNAs and microRNAs in health and disease. Int J Mol Sci; 2016.17(3):356.
17. 15. Gutschner T, Hämmerle M, Diederichs S. MALAT1—aparadigm for long noncoding RNA function in cancer. J Mol Med; 2013.91(7):791-801.
18. 16. Yoshimoto R, Mayeda A, Yoshida M, Nakagawa S. MALAT1 long non-coding RNA in cancer. Biochim Biophys Acta Gene Regul Mech; 2016.1859(1):192-9.
19. 17. Zhang J, Zhang B, Wang T, Wang H. LncRNA MALAT1 overexpression is an unfavorable prognostic factor in human cancer: evidence from a meta-analysis. Int J Clin Exp Med; 2015.8(4):5499.
20. 18. WeiY, Niu B. Role of MALAT1 as a prognostic factor for survival in various cancers: a systematic review of the literature with meta-analysis. Dis Markers; 2015.2015.
21. 19. Wang Y, Xue D, Li Y, Pan X, Zhang X, Kuang B, et al. The long noncoding RNA MALAT-1is a novel biomarker in various cancers: a meta-analysis based on the GEO database and literature. J Cancer; 2016.7(8):991.
22. 20. Leucci E, Patella F, Waage J, Holmstrøm K, Lindow M, Porse B, et al. microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep; 2013.3:2535.
23. 21. Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol; 2015.8(5):4881.
24. 22. Yang Z, Lu W, Ning L, Hao D, Jian S, Hai-Feng C. Downregulation of long non-coding RNA MALAT1 induces tumor progression of human breast cancer through regulating CCND1 expression. Open Life Sci; 2016.11(1):232-6.
25. 23. Zhao Z, Chen C, Liu Y, Wu C. 17β-Estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level. Biochem Biophys Res Commun; 2014.445(2): 388-93.
26. 24. Miao Y, Fan R, Chen L, Qian H. Clinical significance of long non-coding RNA MALAT1 expression in tissue and serum of breast cancer. Ann Clin Lab Sci; 2016.46(4):418-24.
27. 25. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, Loffredo CA, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PloS One; 2012.7(6):e39011.
28. 26. Mohammadi‐Yeganeh S, Mansouri A, Paryan M. Targeting Of miR9/NOTCH1 Interaction ReducesMetastatic Behavior in Triple‐negative Breast Cancer. Chem Biol Drug Des; 2015.86(5):1185-91.
29. 27. Liu X, Luo Z, Peng H, Jiang H, Xu L. Prognostic role of miR-9 expression in various human malignant neoplasms: a meta-analysis. Onco Targets Ther; 2016.9:3039.
30. 28. Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jöckel KH, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes; 2013.6(1):518.
31. 29. Fernandez‐Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, et al. The circulating transcriptome as a source of non‐invasive cancer biomarkers: concepts and controversies of non‐coding and coding RNA in body fluids. J Cell Mol Med; 2015.19(10):2307-23.
32. 30. Liu Y, Sun M, Xia R, Zhang E, Liu X, Zhang Z, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis; 2015.6(7):e1802.
33. 31. Han Y, Liu Y, Zhang H, Wang T, Diao R, Jiang Z, et al. Hsa‐miR‐125b suppresses bladder cancer development by down‐regulating oncogene SIRT7 and oncogenic long non‐coding RNA MALAT1. FEBS Lett; 2013.587(23):3875-82.
34. 32. Zidan HE, Karam RA, El-Seifi OS, Elrahman TMA. Circulating long non-coding RNA MALAT1 expression as molecular biomarker in Egyptian patients with breast cancer. Cancer Genet; 2018.220:32-7.
35. 33. Meseure D, Vacher S, Lallemand F, Alsibai KD, Hatem R, Chemlali W, et al. Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. Br J Cancer; 2016.114(12):1395.
36. 34. Hasanzadeh A, Tanha HM, Ghaedi K, Madani M. Aberrant expression of miR-9 in benign and malignant breast tumors. Mol Cell Probes; 2016.30(5):279-84.
37. 35. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, et al. Epigenetic inactivation of microRNA gene hsa‐mir‐9‐1 in human breast cancer.J Pathol; 2008.214(1):17-24.
38. 36. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res; 2015.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb